IL-27-engineered CAR.19-NK-92 cells exhibit enhanced therapeutic efficacy

Autor(es):Mostrar menos -

Biggi, Alison Felipe Bordini ; Silvestre, Renata Nacasaki ; Tirapelle, Mariane Cariati ; de Azevedo, Julia Teixeira Cottas ; Garcia, Henry David Mogollo ; dos Santos, Matheus Henrique ; de Lima, Sarah Caroline Gomes ; de Souza, Lucas Eduardo Botelho ; Covas, Dimas Tadeu ; Malmegrim, Kelen Cristina Ribeiro ; Figueiredo, Marxa L. ; Picanco-Castro, Virginia

• Tipo de documento: Artigo Científico
• Fonte: CYTOTHERAPY; v. 26, n. 11, p. 11-pg., 2024-10-11.

Resumo

Chimeric antigen receptor (CAR) engineering of natural killer (NK) cells has shown promising results in early- phase clinical studies. However, advancing CAR-NK cell therapeutic efficacy is imperative. In this study, we investigated the impact of a fourth-generation CD19-targeted CAR (CAR.19) coexpressing IL-27 on NK-92 cells. We observed a significant improvement in NK-92 cell proliferation and cytotoxicity activity against B-cell cancer cell lines, both in vitro and in a xenograft mouse B-cell lymphoma model. Our systematic transcriptome analysis of the activated NK-92 CAR variants further supports the potential of IL-27 in fourth-generation CARs to overcome limitations of NK cell-based targeted tumor therapies by providing essential growth and activation signals. Integrating IL-27 into CAR-NK cells emerges as a promising strategy to enhance their therapeutic potential and elicit robust responses against cancer cells. These findings contribute substantially to the mounting evidence supporting the potential of fourth-generation CAR engineering in advancing NK cell-based immunotherapies. (c) 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) (AU)

• Processo FAPESP: 13/08135-2 - CTC - Centro de Terapia Celular
• Beneficiário: Dimas Tadeu Covas
• Modalidade de apoio: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs
• Processo FAPESP: 19/25309-0 - NK-CAR (off-the-shelf) para o tratamento de Leucemias e Linfomas
• Beneficiário: Virginia Picanço e Castro
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 20/08279-8 - Estabelecimento de uma plataforma para geração de células NK-CAR com maior eficácia terapêutica in vitro e in vivo
• Beneficiário: Júlia Teixeira Cottas de Azevedo
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 20/07055-9 - Núcleo de Terapia Celular - NuTeC
• Beneficiário: Rodrigo do Tocantins Calado de Saloma Rodrigues
• Modalidade de apoio: Auxílio à Pesquisa - Núcleos de Pesquisa Orientada a Problemas em São Paulo